论文部分内容阅读
目的 :探讨单核细胞趋化蛋白 1单克隆抗体 (MCP 1mcAB)或Losartan拮抗血管紧张素Ⅱ (AngⅡ )介导的血管平滑肌细胞 (VSMCs)增殖与迁移效应的可能性 ,为防治动脉硬化 (AS)提供一定的理论依据。方法 :采用改良的Boyden小室法检测VSMCs的迁移效应 ;以MTT法、3H TdR掺入法、3H 脯氨酸标记法和VSMCs计数评价VSMCs的增殖效应 ;将培养的VSMCs分为 5组 :2 %胎牛血清 ( 2 %FCS)组、AngⅡ组 (其浓度为 10 - 1 0 ～ 10 - 6 Mol/L)、Losartan组 (其浓度为 10 - 7～ 10 - 5Mol/L)、MCP 1mcAb组 (终浓度为 10 μg/ml)和阳性对照组 (含 5 %的酵母多糖活化血清 )。结果 :( 1)AngⅡ具有剂量依赖性地促进VSMCs的增殖与迁移效应 ;( 2 )MCP 1mcAb、Losartan能有效地拮抗AngⅡ介导的VSMCs增殖与迁移效应。结论 :MCP 1mcAb、Losartan拮抗VSMCs的增殖与迁移效应为其防治AS提供一定的理论依据。
Objective: To investigate the possibility of proliferation and migration of vascular smooth muscle cells (VSMCs) mediated by MCP1mcAB or Losartan antagonist angiotensin Ⅱ (AngⅡ) ) Provide some theoretical basis. Methods: The migration of VSMCs was detected by the modified Boyden chamber method. The proliferative effects of VSMCs were evaluated by MTT assay, 3H-TdR incorporation, 3H-proline labeling and VSMCs counting. The cultured VSMCs were divided into 5 groups: 2% Fetal calf serum (2% FCS), AngⅡ (10-10 ~ 10-6 mol / L), Losartan (10-7-10-5Mol / L), MCP1mcAb Final concentration of 10 μg / ml) and positive control group (containing 5% of zymosan activated serum). Results: (1) Ang II promoted the proliferation and migration of VSMCs in a dose-dependent manner; (2) Losartan and MCP 1mcAb could effectively antagonize the effect of AngⅡ on the proliferation and migration of VSMCs. CONCLUSION: The effects of MCP 1mcAb and Losartan on the proliferation and migration of VSMCs provide a theoretical basis for their prevention and treatment.